Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on December 7, 2022. The filing details the results of the company's 2022 annual meeting of stockholders held on that date. AgeX is an emerging growth company incorporated in Delaware with its principal executive offices in Alameda, California.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only quantitative data provided relates to share counts and voting results.
- Shares Outstanding (Record Date): 37,947,152
- Shares Represented at Meeting: 26,899,366 (70.89% of voting power)
Material Changes and Corporate Actions
Stockholders approved several significant amendments and proposals at the annual meeting:
- Authorized Share Increase: Approved an amendment to the Certificate of Incorporation to increase authorized common stock from 100,000,000 to 200,000,000 shares.
- Equity Plan Expansion: Approved an amendment to the 2017 Equity Incentive Plan to add 4,000,000 shares available for equity awards.
- Juvenescence Proposal: Approved a proposal permitting Juvenescence Limited to acquire additional shares via warrant exercise or loan conversion, even if it results in ownership exceeding 19.9% or 50% of outstanding stock, subject to specific pricing conditions.
- Director Elections: Elected four directors: Gregory Bailey, Joanne Hackett, Michael May, and Michael D. West.
- Accountant Ratification: Ratified the selection of WithumSmith + Brown PC as independent registered public accountants for fiscal year 2022.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, revenue outlook, or management commentary regarding operational performance. It includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially due to risk factors detailed in other periodic reports. The filing does not disclose specific new risks or contingencies beyond the standard legal disclaimers.
Investor Verification Checklist
- Verify the impact of the 100 million share increase on potential future dilution.
- Review the terms of the "Juvenescence Proposal" to understand the conditions under which Juvenescence Limited may increase its stake.
- Confirm the total number of shares now available under the amended 2017 Equity Incentive Plan.
- Check subsequent filings for the actual issuance of shares under the new equity plan or the Juvenescence agreement.